Economic evaluation and clinical trials: Size matters

British Medical Journal

Volumn 321, Issue 7273, 2000, Pages 1362-1363

  Briggs, A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; ECONOMIC ASPECT; EDITORIAL; HEALTH CARE DELIVERY; LONG TERM CARE; MEDICAL ETHICS; PRIORITY JOURNAL;

EID: 0034598129     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.321.7273.1362     Document Type: Editorial

References (9)

1. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. I: Clinical effectiveness
2. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. II: Cost effectiveness
3. Economic evaluation of pharmaceuticals: Frankenstein's monster or vampire of trials?
4. The distribution of health care costs and their statistical analysis for economic evaluation
5. Sample size and power calculations for stochastic cost-effectiveness analysis
6. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 'negative' trials
7. Estimation rather than hypothesis testing: Confidence intervals rather than P values
8. Statistics notes: Absence of evidence is not evidence of absence